Abstract
Chronic lymphocytic leukemia (CLL) is the most common leukemia in western countries, it has no cure and pharmacological refractoriness to current treatments are common. Indole-3-carbinol (I3C) presents pharmacological activity against CLL. KV1.3 potassium channels are involved in B-cell function, cell cycle regulation and proliferation, being considered a new therapeutic target. We aim to determine if I3C can act, in part, by modulating KV1.3 function and the molecular requirements of I3C and derivatives for channel binding.The inhibitory effect of I3C on KV1.3 currents was assessed in I3C sensitive (I3CS-CLL) or resistant (I3CR-CLL) cells.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
